Trasylol

 

Trasylol (generic Aprotinin) is a popular blood-clotting drug commonly used after heart surgery. Manufactured by Bayer AG pharmaceuticals, this injectable drug nearly doubles the risk of kidney failure and stroke and increases the risk of heart attack or heart failure (ischemic events) by over 50 %. On January 26, 2006 a study published in the New England Journal of Medicine (Mangano, et al) reported these alarming findings after following over 4000 heart by-pass surgery patients. Since February 9, 2006 the FDA has urged doctors to limit the use of Bayer AG’s Trasylol pending further agency review.

Trasylol is used to control bleeding, but has been linked to serious side effects such as kidney failure, heart attacks, strokes, and encephalopathy (damage to brain tissue).

Trasylol increases the risk of heart attack, heart failure and kidney failure.  If you were given Trasylol during or after surgery and suffered a heart attack or stroke, encephalopathy, or kidney failure, you may wish to learn more about your legal options Trasylol, manufactured by Bayer HealthCare Pharmaceuticals, has been linked to severe side effects such as kidney failure, cardiovascular problems, and brain damage. Renal failure is the condition where the kidneys fail to function properly. Physiologically, renal failure is described as a decrease in the glomerular filtration rate. Clinically, this manifests in an elevated serum creatinine. It can broadly be divided into two categories: acute renal failure and chronic renal failure.

 

 

Chronic renal failure (CRF) develops slowly and gives few symptoms initially. It can be the complication of a large number of kidney diseases, such as IgA nephritis, glomerulonephritis, chronic pyelonephritis and urinary retention. End-stage renal failure (ESRF) is the ultimate consequence, in which case dialysis is generally required while a donor for renal transplant is found.

Acute renal failure (ARF) is, as the name implies, a rapidly progressive loss of renal function, generally characterized by oliguria (decreased urine production, quantified as less than 400 to 500 mL/day in adults, less than 0.5 mL/kg/h in children or less than 1 mL/kg/h in infants), body water and body fluids disturbances and electrolyte derangement. An underlying cause must be identified to arrest the progress, and dialysis may be necessary to bridge the time gap required for treating these underlying causes.

Acute renal failure can present on top of (i.e. in addition to) chronic renal failure. This is called acute-on-chronic renal failure (AoCRF). The acute part of AoCRF may be reversible and the aim of treatment, like in ARF, is to return the patient to his/her baseline renal function, which is typically measured by serum creatinine. AoCRF, like ARF, can be difficult to distinguish from chronic renal failure, if the patient has not been followed by a physician and no baseline (i.e. past) blood work is available for comparison.

Trasylol in the News

Bayer Hides Results of Trasylol Risks

 

 









Ashkin Law Firm
Roberta Ashkin, Esq.
300 East 42nd St. 14th Fl
New York New York 10017
Telephone: (646) 779 8520
Facsimile: (212) 593 9997
» click here to locate our office